ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2023
November 09, 2023 08:00 ET
|
ProPhase Labs, Inc.
Company sees significant momentum in Pharmaloz, Nebula Genomics and ProPhase BioPharma Pharmaloz Manufacturing plans on track to increase capacity from $10 million to over $75 million in 2024...
ProPhase Labs Announces Record First Quarter 2022 Financial Results
May 13, 2022 08:30 ET
|
ProPhase Labs, Inc.
Record Net Revenues of $47.5 Million, Up 211% Year-over-Year Record Net Income of $12.5 Million, Increasing 1082% Year-over-Year Announces Special Cash Dividend of $0.30 per...
ProPhase Labs to Present at the Q4 Investor Summit Conference
November 10, 2021 08:30 ET
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at...
ProPhase Labs Begins Advanced, Saliva-based Viral PCR Multiplex-Testing for COVID-19, Influenza A & B, and Other Viruses After FDA Confirmation of Two Emergency Use Authorizations
February 09, 2021 08:30 ET
|
ProPhase Labs, Inc.
Company Integrates Spectrum Solutions™ SDNA-1000 Saliva Collection System for Advanced, Simultaneous Multi-Viral Detection of Infections and Viral Mutations GARDEN CITY, NY, Feb. 09, 2021 ...
ProPhase Labs Completes Acquisition of CLIA Accredited Lab and Provides Corporate Update
November 02, 2020 08:30 ET
|
ProPhase Labs, Inc.
DOYLESTOWN, Pennsylvania, Nov. 02, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has completed the...
ProPhase Labs Announces Definitive Agreement to Acquire CLIA Accredited Lab Certified for COVID-19 and Upper Respiratory Testing
October 23, 2020 08:30 ET
|
ProPhase Labs, Inc.
DOYLESTOWN, Pennsylvania, Oct. 23, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today a definitive agreement to...